Xanthigen for weight loss and metabolic health in adults with overweight
Effects of Xanthigen on Weight Control and Metabolic Variables in Overweight Individuals
This 16-week randomized, triple-blind test will see if taking a daily Xanthigen capsule (300 mg or 600 mg) helps adults aged 20–50 with BMI 27–29.9 lose weight and improve metabolic blood tests compared with a placebo.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 180 (estimated) |
| Ages | 20 Years to 50 Years |
| Sex | All |
| Sponsor | Universidad Católica San Antonio de Murcia Academic / other |
| Locations | 1 site (Murcia, Murcia) |
| Trial ID | NCT07519980 on ClinicalTrials.gov |
What this trial studies
This single-center, randomized, controlled, triple-blind trial assigns eligible adults to one of three parallel groups receiving 0 mg (placebo), 300 mg, or 600 mg Xanthigen once daily for 16 weeks, taken in the morning on an empty stomach. Participants will be asked to maintain their usual diet and physical activity while undergoing scheduled anthropometric measurements, physical activity monitoring, and blood tests to track metabolic and biochemical variables. All groups receive identical visits and assessments to preserve blinding and comparability. The main outcomes are changes in body weight and key metabolic markers over the 16-week period.
Who should consider this trial
Good fit: Adults aged 20–50 with a BMI of 27.0–29.9 kg/m2 who are in generally good physical and mental health, desire to lose weight, and are not taking chronic medications for metabolic or cardiovascular conditions are the intended participants.
Not a fit: People with BMI outside the 27–29.9 range, or with diabetes, hypertension, hyperlipidemia, cardiovascular or thyroid disease, or those on chronic medications are excluded and would not be represented by this trial's results.
Why it matters
Potential benefit: If successful, daily Xanthigen could provide a simple supplement to help people with overweight lose weight and improve metabolic markers such as blood sugar and lipids.
How similar studies have performed: Prior small studies and supplement trials of Xanthigen or related compounds have reported modest weight-loss signals, but the evidence is limited and not consistently replicated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The subject is able and willing to follow the study protocol procedures to sign the informed consent form prior to the evaluations. * Participants must be between 20 and 50 years of age at the time of consent. * The subject is in good physical and mental health as determined by medical history, physical examination, electrocardiogram, vital signs, biochemistry, and hematology results. * Participants must have a BMI between 27 and 29.9 kg/cm2. * Desire to lose weight. Exclusion Criteria: * Relevant medical history or presence of any medical condition that could interfere with this study, such as a previous diagnosis of diabetes, hypertension, hyperlipidemia, cardiovascular disease, thyroid disease, asthma, arthritis, or inflammatory conditions. * Fasting blood sugar levels greater than 125 mg/dL and/or total cholesterol levels greater than or equal to 240 mg/dL. * Blood pressure levels below 90/140 mm Hg (diastolic/systolic). * Chronic intake of medications/dietary supplements with an impact on body weight or body composition or lipid-modifying products (e.g., protein shakes, statins, omega-3 fatty acids, etc.) 2 months prior to selection or during the study. * Known allergy/sensitivity to any of the components of the investigational product. * Change in hormonal contraception or any use of hormone replacement therapy (HRT) during or at least 3 months prior to the study (if female). * Women of childbearing age who are pregnant or intend to become pregnant during the study period. * Use of any dietary supplements (except mineral supplements, e.g., Ca, Mg). * Participation in any weight loss intervention or recent change in body weight \> 4.5 kg during the last 9 months. * History and/or presence of eating disorders such as bulimia, anorexia nervosa, or binge eating, as determined by the investigator. * Consumption of any dietary supplements (except mineral supplements, e.g., Ca, Mg). * Participation in any weight loss program or recent change in body weight \> 4.5 kg during the last 9 months. * History and/or presence of eating disorders such as bulimia, anorexia nervosa, binge eating, as determined by the investigator. * Individuals who currently participate in aerobic exercise more than 4 times per week, or more than 2.5 hours per week. * Vegan lifestyle. * Current smoker or user of nicotine products or cessation of smoking within 1 year of the screening date. * Gastrointestinal diseases/conditions (colitis ulcers, Crohn's disease, peptic ulcers, celiac disease).
Where this trial is running
Murcia, Murcia
- UCAM HiTech, Sport & Health Innovation Hub — Murcia, Murcia, Spain (Recruiting)
Study contacts
- Study coordinator: Francisco Javier López Román, Medical degree
- Email: jlroman@ucam.edu
- Phone: +157 968278157
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.